Summary The SARS-CoV-2 Omicron variant escapes neutralizing antibodies elicited by
vaccines or infection. However, whether Omicron triggers cross-reactive humoral responses …

The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and
South Africa,. It has in the meantime spread to many countries and is expected to rapidly …

Omicron, the most recent SARS-CoV-2 variant of concern (VOC), harbours multiple
mutations in the spike protein that were not observed in previous VOCs. Initial studies …

The Omicron variant of SARS-CoV-2 has been shown to evade neutralizing antibodies
elicited by vaccination or infection. Despite the global spread of the Omicron variant, even …

Background and Methods The SARS-CoV-2 (severe acute respiratory syndrome
coronavirus 2) Omicron (B. 1.1. 529) variant is the antigenically most distinct variant to date …

Abstract SARS-CoV-2 Delta and Omicron are globally relevant variants of concern. Although
individuals infected with Delta are at risk of developing severe lung disease, infection with …

Background SARS-CoV-2 vaccines currently authorized for emergency use have been
highly successful in preventing infection and lessening disease severity. The vaccines …

The severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is spreading rapidly, even in vaccinated individuals, raising concerns about immune …

The spread of the Omicron SARS-CoV-2 variant underscores the importance of analyzing
the cross-protection from previous non-Omicron infection. We have developed a high …

SARS-CoV-2 variants accumulating immune escape mutations provide a significant risk to
vaccine-induced protection against infection. The novel variant of concern (VoC) Omicron …